Today, I want to talk to you about a stock that has been doing very well for my New World Investor subscribers. This biotech stock recently ran up almost to my $12 target price and then pulled back. Then, last Wednesday, they had an analyst meeting that was so positive the stock jumped almost 22%. Have I sparked your interest yet? If not then read on, because there's plenty more to love about this biotech stock.

I first recommended this winning stock last June 14 at $4.50. It hit $11.63 last October, after I raised the target price from $8 to $12, but then backed off in the general aversion to development-stage stocks as investors' risk appetite vanished. Then, the day before the stock's analyst meeting, the company presented results to the International Society for Prenatal Diagnostics at their meeting in Vancouver. Their ground-breaking Down syndrome test correctly identified 100% of Down syndrome samples, with no false positives. They have 10 fetal genetic markers now, which cover 93% of all U.S. ethnic groups. Previously, they had eight genetic markets and showed greater than 95% sensitivity (identifying Down syndrome) and greater than 95% specificity (avoiding false positives). That was good enough for approval, as the existing noninvasive prenatal diagnostic techniques are only 70% to 90% accurate. In fact, due to the dangers of amniocentesis before our daughter was born, my wife opted for an x-ray/blood test last year even though it was less accurate. Had this company's new test been available then I know she would have opted for it in a heartbeat.

With a ground-breaking medical presentation like that, one could already sense what an uplifting effect it would have on the company's analyst meeting. Going forward, this biotech stock will start a multi-site prospective study in the fourth quarter, targeting a launch as a Laboratory Developed Test in the first half of 2009. Their Rh-factor test is available now to partner labs, and they will start a validation trial in the September quarter targeting FDA approval. This was a blow-away presentation, and I expect the stock to consolidate a bit and then march on to my $12 target. Now is an excellent time to buy shares of this innovative biotech stock. Why wait? Subscribe today and begin receiving your own weekly New World Investor Radar Reports where you'll learn about this excellent stock and so many more.